Global Musculoskeletal Partnering 2015-2022: Deal trends, players and financials

Current Partnering
400+ Pages - WILD10971
$3,495.00

Global Musculoskeletal Partnering 2015 to 2022 provides the full collection of Musculoskeletal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2015.

Trends in Musculoskeletal partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Musculoskeletal partnering agreement structure
Musculoskeletal partnering contract documents
Top Musculoskeletal deals by value
Most active Musculoskeletal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.
The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Musculoskeletal dealmaking trends.


Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Musculoskeletal dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Musculoskeletal deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active Musculoskeletal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Musculoskeletal deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Musculoskeletal partnering deals by specific Musculoskeletal target announced since 2015. The chapter is organized by specific Musculoskeletal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Musculoskeletal partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Musculoskeletal technologies and products.

Report scope

Global Musculoskeletal Partnering 2015 to 2022 is intended to provide the reader with an in-depth understanding and access to Musculoskeletal trends and structure of deals entered into by leading companies worldwide.

Global Musculoskeletal Partnering 2015 to 2022 includes:

Trends in Musculoskeletal dealmaking in the biopharma industry since 2015
Access to headline, upfront, milestone and royalty data
Access to hundreds of Musculoskeletal deal contract documents
Comprehensive access to over 600 Musculoskeletal deal records
The leading Musculoskeletal deals by value since 2015
Most active Musculoskeletal dealmakers since 2015


The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthriti, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.


In Global Musculoskeletal Partnering 2015 to 2022, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Musculoskeletal Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

'

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Musculoskeletal dealmaking

2.1. Introduction
2.2. Musculoskeletal partnering over the years
2.3. Musculoskeletal partnering by deal type
2.4. Musculoskeletal partnering by industry sector
2.5. Musculoskeletal partnering by stage of development
2.6. Musculoskeletal partnering by technology type
2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 –Financial deal terms for Musculoskeletal partnering

3.1. Introduction
3.2. Disclosed financials terms for Musculoskeletal partnering
3.3. Musculoskeletal partnering headline values
3.4. Musculoskeletal deal upfront payments
3.5. Musculoskeletal deal milestone payments
3.6. Musculoskeletal royalty rates

Chapter 4 – Leading Musculoskeletal deals and dealmakers
4.1. Introduction
4.2. Most active in Musculoskeletal partnering
4.3. List of most active dealmakers in Musculoskeletal
4.4. Top Musculoskeletal deals by value

Chapter 5 – Musculoskeletal contract document directory

5.1. Introduction
5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 – Musculoskeletal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Musculoskeletal therapeutic target

Appendices
Appendix 1 – Directory of Musculoskeletal deals by company A-Z since 2015
Appendix 2 – Directory of Musculoskeletal deals by deal type since 2015
Appendix 3 – Directory of Musculoskeletal deals by stage of development since 2015
Appendix 4 – Directory of Musculoskeletal deals by technology type since 2015

Further reading on dealmaking

Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures
Figure 1: Musculoskeletal partnering since 2015
Figure 2: Musculoskeletal partnering by deal type since 2015
Figure 3: Musculoskeletal partnering by industry sector since 2015
Figure 4: Musculoskeletal partnering by stage of development since 2015
Figure 5: Musculoskeletal partnering by technology type since 2015
Figure 6: Musculoskeletal partnering by indication since 2015
Figure 7: Musculoskeletal deals with a headline value
Figure 8: Musculoskeletal deals with upfront payment values
Figure 9: Musculoskeletal deals with milestone payment
Figure 10: Musculoskeletal deals with royalty rates
Figure 11: Active Musculoskeletal dealmaking activity since 2015
Figure 12: Top Musculoskeletal deals by value since 2015

3D-Side, 3SBio, A2A Pharmaceuticals, Aavis Pharmaceuticals, Abarca, Abbvie, AbCellera, AC Bioscience, Accenture, Actigraph, Activbody, Active Implants, Adaptive Health, Additive Orthopaedics, Advanced Human Imaging, AdventHealth, Affinia Therapeutics, AGC Asahi Glass, AgNovos Healthcare, AgomAb Therapeutics, Akashi Therapeutics, AKL Research and Development, AlfaMed, Aligos Therapeutics, AliMed, Alkem Laboratories, Allergan, AlloSource, Almirall, Alpine Immune Sciences, Altamira Bio, Altasciences, Alvogen, Alvotech, Ambry Genetics, Amedica, Amend Surgical, American Association of Neuromuscular & Electrodiagnostic Medicine, Amgen, Amneal Pharmaceuticals, AMRA, AMRA Medical, Anagenesis Biotechnologies, Analysis Group, AnaMar, Angelini Pharma, Angers University, Anika Therapeutics, ANI Pharmaceuticals, Antares Pharma, Antibe Therapeutics, Apexigen, Apple, Apsen Farmacutica, Aptahem, Aptorum Group, Aralez Pharmaceuticals, Aratana Therapeutics, Aravive Biologics, argenx, ARK Crystal, Arrowhead Pharmaceuticals, Arthrex, Arthrosi Therapeutics, Artialis, Asahi Kasei, Ascendis Pharma, AskAt, Asklepios Biopharmaceutical, Assertio Therapeutics, Astellas Pharma, AstraZeneca, Athrotech, Atnahs Pharma, Audentes Therapeutics, Aurinia Pharmaceuticals, Australian Research Council, Autotelic BIO, Avalere Health, Avanos Medical, Aveta Biomics, AveXis, Avidity Biosciences, Avion Pharmaceuticals, AWB Schraubtechnik und Industriebedarf, Axovant Gene Therapies, Azellon Cell Therapeutics, Aziyo Biologics, Back-A-Line, Bacterin International, Baebies, Bamboo Therapeutics, Bauerfeind, Baxalta, Bayer, Baylor College of Medicine, Bazis NN, BC Platforms, Beijing Tide Pharmaceutical, Benitec Biopharma, Berg, BGI, BillionToOne, Bio-Thera Solutions, BioAge Labs, BioCanRx, Biocomposites, Biogen, BioGen Medical, Biohaven Pharmaceuticals, BioInvent, BioMarin Pharmaceutical, BioMed X Innovation Center, BionX Medical Technologies, BioPharma Forest, Bioqube Ventures, Bioservo Technologies, Biosolution, Biosplice, Bioventus, BioVinc, Bison & Rose, Blue Belt Technologies, Blueprint Medicines, Bodycad, Boehringer Ingelheim, Bone Biologics, Bone Therapeutics, Brickell Biotech, Brigham and Women's Hospital, Bristol-Myers Squibb, BRM Extremities, BSN Medical, Burke Therapeutics, c-LEcta, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Calimmune, Calliditas Therapeutics, Camargo Pharmaceutical Services, Camber Spine Technologies, Can-Fite BioPharma, CANbridge Pharmaceuticals, Cantargia, Capricor Therapeutics, Capsigen, CareFirst BlueCross BlueShield, Carlsmed, Carna BioSciences, CartiHeal, Cartiva, CAS, Casper Pharma, Catabasis Pharmaceuticals, Catalyst Pharmaceuticals, cbdMD, Cedars-Sinai Medical Center, Celgene, Celltech, Cellthera Pharma, Cell Therapy Catapult, Celltrion, Cellular Biomedicine, Cel Sci, Centinel Spine, Centogene, Cerhum, Changshan Pharm, Charles River Laboratories, CheckPoint Immunology, Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Research Institute, Chronolife, Chugai Pharmaceutical, CHU Sainte-Justine, Cigna Healthcare, Cipher Pharmaceuticals, Cipla, Clementia Pharmaceuticals, Clinical Graphics, CMS Medical, Coapt, Cocoon Biotech, Codiak BioSciences, Coeptis Pharmaceuticals, Coherus Biosciences, Collaborative Trajectory Analysis Project, Collagen Solutions Plc, College Park Industries, Collplant, Colorado HealthOP, Colorado State University, Columbia University, Columbia University Medical Center, Complix, ConforMIS, Consensus Orthopedics, Consortium AI, Control Bionics, Conventus Orthopaedics, Coracoid Solutions, Corin, Cortexyme, CRISPR Therapeutics, CrystalGenomics, CSIR-Central Drug Research Institute, CSPC Pharmaceutical Group, Cumberland Pharmaceuticals, Curasan, Cure Duchenne, CURE Pharmaceutical, Cure SMA, CurveBeam, CymaBay Therapeutics, Cytoo, Cyxone, Daewoong Pharmaceutical, Daiichi Sankyo, Dalhousie University, Debiopharm, Defense Advanced Research Projects Agency, Delivra, Delpor, Denali Therapeutics, Department of Defense, Department of Veterans Affairs, DePuy, Desma HC, Dimension Therapeutics, Distributed Bio, DJO Global, DJO Surgical, DMD Therapeutics, Dong-A ST, Dr. Reddy's Laboratories, Duchenne UK, Duke University, Dynacure, Dyne Therapeutics, Dyno Therapeutics, Echolight Medical, ECM Therapeutics, Edge Medical, EGeen, Eisai, Elanco, Eli Lilly, Ellipse Technologies, Eluthia, Ember Therapeutics, Embryo Ventures, EmergeOrtho, Emory University, Emovi, Endo Pharmaceuticals, Endo Ventures, Energy Medicine Research Institute, Engage Surgical, Enleofen Bio, Enzene Biosciences, EOS Imaging, Epirus Biopharmaceuticals, Equillium, Ethos Research & Development, Ethypharm, Eurofins LifeCodexx, Europe Technologies, Eversana, Evonik Industries, Evotec, Ewopharma, Exactech, Exagen Diagnostics, ExCEEd Orphan, Exicure, Exonics Therapeutics, Exothera, Exzell Pharma, Facio Therapies, Fagron, Feinstein Institute for Medical Research, Ferring Pharmaceuticals, Fibrocell Science, Fidelta, Fin-ceramica faenza spa, Flexion Therapeutics, Fluidigm, Food and Drug Administration (FDA), Forbius, Forge Biologics, Foundation to Eradicate Duchenne, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Friedreichs Ataxia Research Alliance, FSHD Global Research Foundation, Fujifilm Kyowa Kirin Biologics, Fulcrum Therapeutics, Fuse Medical, G3 Therapeutics, Galapagos, Galderma, Galecto, Galvani Bioelectronics, Gebro Pharma, Geisinger Health System, Geistlich Pharma, GenEdit, GeneQuine Biotherapeutics, General Electric (GE), Genethon, Geneva Foundation, Genevant Sciences, Genkyotex, Gennao Bio, Genome BC, Genome Canada, Genticel, George Washington University, GetHealthy, Gilead Sciences, GlaxoSmithKline, Global Orthopaedic Technology, Globus Medical, Graminex, Graviton Bioscience, Gravocore, Great Ormond Street Hospital (GOSH), Grunenthal, Guangzhou Ruianbo Pharmaceutical Technology, Guangzhou Ruiao Biopharmaceutical Technology, Hackensack University Medical Center, Hadasit Medical Research Services and Development, Haisco Pharmaceutical, Hanmi Pharmaceutical, Hansa Biopharma, Hanuman Pelican, Harmonic Bionics, Harvard University, HAYA Therapeutics, Health2Work, Healthcare Royalty Partners, HealthSnap, Healthy Directions, HemoShear, Highland Instruments, High Line Bio, Hikma Pharmaceuticals, Histogenics, HistoIndex, Hoffmann La Roche, Horizon 2020, Horizon Pharma plc, Horizon Therapeutics, Hospital for Special Surgery, H Robotics, Human Life CORD Japan, Huntsworth Health, I-mab, IDIPharma, Idorsia, IGEA Clinical Biophysics, Iktos, IM-Tech, ImageBiopsy Lab, IMASCAP, Imcyse, Immune Pharmaceuticals, Impact Cryotherapy, Impressio, In2Bones USA, Incyte, Indiana University, Innosuisse, Innosurge, Innovate UK, Innovus Pharmaceuticals, Inovalon, Inserm, Insilico Biotechnology, Integra LifeSciences, Integrum, Intel, Interleukin Genetics, Intermountain Healthcare, International Spine Study Group Foundation, IntraFuse, Intrexon, Inventiva, Invibio Biomaterial Solutions, Invitae, Ionis Pharmaceuticals, Ipsen, IQVIA, Iroko Pharmaceuticals, Ironwood Pharmaceuticals, ISA Scientific, Italfarmaco, IthenaPharma, Iturri, Izana Bioscience, Jackson Laboratory, Jain Foundation, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Japan Medical Dynamic Marketing, Jesse's Journey, Jiangsu Aosaikang Pharmaceutical, Jiangsu Tainuo, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jointpoint, Jubilant Pharma, Jubilant Radiopharma, Jubilant Therapeutics, Juvena Therapeutics, Juvenescence, Juvenomics, JW Pharmaceutical, Kalytera Therapeutics, Kansas State University, Karolinska Institute, Kashiv BioSciences, Kawasaki Medical School, Keck Graduate Institute of Applied Life Sciences, Keck School of Medicine of USC, Kelyniam Global, Kennedy Institute of Rheumatology, Kennedy Trust For Rheumatology Research, KFx Medical, KineMed, Kiniksa Pharmaceuticals, Kitov Pharma, Kolon Life Science, Konica Minolta, Kowa Pharmaceuticals America, Kuhnil Pharmaceuticals, Kuros Biosciences, KYE Pharmaceuticals, Kyocera, Laboratories Acbel, LABORATORIOS SAVAL, Laboratory Corporation of America, Laurel Venture Capital, Lawson Health Research Institute, Leadiant Biosciences, Lead Pharma, Les Laboratoires Servier, Level Brands, Lexicon Pharmaceuticals, LifeArc, Lifehealthcare, Ligand Pharmaceuticals, Lima Corporate, Link Health, Litha Pharma, LNE/G-Med, Locana, Lonza, Ludwig Institute for Cancer Research, Lumicera Health Services, Lupin, Lynk Pharmaceuticals, Maastricht University, MainPointe, Marathon Pharmaceuticals, Mariel Therapeutics, Marina Biotech, Maryland Stem Cell Research Fund, Massachusetts General Hospital, Materialise, Maxiim, Maxx Medical, Mayo Clinic, MC10, McMaster University, MDA Venture Philanthropy, Medac, Medacta, Medexus Pharmaceuticals, Mediar Therapeutics, Medical Enterprises Distribution, Medidata Solutions, MedImmune, Medolife Rx, Medosome Biotec, Medovex, MedRhythms, Medservice, MedShape, Medtronic, Merck and Co, Merck KGaA, Mereo BioPharma, Mesoblast, Methuselah Foundation, Metrion Biosciences, MHC Medical Products, Microdrop, Miravo Healthcare, Mithra Pharmaceuticals, Mitsubishi Tanabe Pharma, Mobelife, Moberg Pharma, Modernizing Medicine, Moebius Medical, Momenta Pharmaceuticals, Montana Board of Research and Commercialization Technology, MoonLake Immunotherapeutics, Morphic Therapeutic, MorphoSys, Morris Animal Foundation, Motorika, mSKIL, MTF Biologics, Mundipharma, Murdoch Childrens Research Institute, Muscle Activation Technique, Muscular Dystrophy Association, Mylan Laboratories, Mylan Pharmaceuticals, Myomo, Myonexus Therapeutics, MYOS, Myosana Therapeutics, Myriad Genetics, Myrtle Potter & Company, myTomorrows, Nanotherapeutics, National Center for Complementary and Alternative Medicine, National Human Genome Research Institute, National Institute for Health Research (NIHR), National Institute of Arthritis and Musculoskeletal Diseases, National Institute on Aging, National Institutes of Health, National Psoriasis Foundation, National Science Foundation, Nationwide Children’s Hospital, Navidea Biopharmaceuticals, Navitas, NEMO Health, NeoDynamics, Nestle, Neurocrine Biosciences, NeuroMuscular Orthotics, Neuronoff, NeuroVive Pharmaceutical, NeuTec Pharma, NeuX Technologies, New York University, New York University School of Medicine, New Zealand Pharmaceuticals, Nextera, Nextremity Solutions, NHS Blood and Transplant, Nippon Shinyaku, Nordic Bioscience, Nordic Pharma Group, Northway Biotechpharma, Northwestern University, NovaQuest, Novara Therapeutics, Novare Pharmaceuticals, Novartis, Novation, Novosteo, NT Pharma, Nuevolution, Numotion, Nuritas, NuVasive, Nuvo Research, nView Medical, Ohio State Innovation Foundation, Ohio State University, Omeros, OncoArendi Therapeutics, Oncodesign, Onkos Surgical, Ono Pharmaceutical, Open University of Israel, OPUM, Orebro University, Organovo, Origo Biopharma, Orsini Healthcare Specialty Pharmacy, Orthocell, Orthofix, OrthogenRx, OrthoGrid Systems, OrthoGrow, Orthopaedic Foot & Ankle Center, Orthopaedic Research UK, Ortho Regenerative Technologies, OrthoSensor, Ortho Transmission, Ortoma, OSSIS, Ossur, Osteolabs, Osteopore International, Ottobock, OxyPharma, Pacira Biosciences, Padlock Therapeutics, Paladin Labs, Paragon 28, ParcelShield, Parent Project Muscular Dystrophy, Parvizi Surgical Innovation, Patheon, Patient-Centered Outcomes Research Institute (PCORI),, PDL BioPharma, Pennsylvania State University, PeptiDream, Peptinnovate, Pfenex, Pfizer, Pfizer Canada, Pfizer Japan, PharmaLegacy Laboratories, Pharmalink AB, PharmaLynk, Pharmapark, Physimax Technologies, Piramal Healthcare, Pluristem Therapeutics, Poietis, Polpharma, Prasco Laboratories, Precision BioSciences, Pregene Biopharma, Premier Inc, Prime Therapeutics, PrinterPrezz, Promedior, Prometheus Laboratories, Promimic, Propella Therapeutics, Provider Network of America, PsychoGenics, PTC Therapeutics, pt Health, Purdue Pharma, Purdue Research Foundation, Quanta, Queen Mary University of London, Quinn Medical, Radius Health, Raffles PharmaTech, Rainbow Medical, Ramot at Tel Aviv University, Rebel Edibles, Recombinetics, Recursion, Regen BioPharma, Regeneron Pharmaceuticals, Regeneus, RegenLab, Regenstrief Institute, Regenxbio, ReGenX Biosciences, Rehabtronics, Remedium Bio, Renovis, Replicel Life Sciences, Resonant Specific Technologies, Responsive Orthopedics, RevBio, ReveraGen BioPharma, Revolo Biotherapeutics, Rheumatology Research Foundation, Rhino Assembly, Rigenerand, Riptide Bioscience, RMX Biopharma, Roche, Rocket Pharmaceuticals, ROMEG Therapeutics, Royalty Pharma, Saint Louis University, SAMIL Pharm, Samsung Bioepis, Sanford Burnham Institute, Sangamo Therapeutics, Sanguine, Sanofi, Santhera Pharmaceuticals, Saol Therapeutics, Saphetor, Sarepta Therapeutics, Satellos Bioscience, SAVSU Technologies, Sayre Therapeutics, Science Biotech, ScinoPharm Taiwan, Scipher Medicine, Scripps Research Institute, Scriptr Global, Second Genome, SecondWave Systems, Seikagaku, Selecta Biosciences, Selexis, Selvita, Sermonix Pharmaceutical, Shionogi, Shire Pharmaceuticals, Si-Bone, Sierra Oncology, Simcere Pharmaceuticals, SinoVeda Canada, SiSaf, Sites Medical, SIT Laboratorio Farmaceutico, Skyhawk Therapeutics, Smith & Nephew, Sofregen Medical, Solid Biosciences, SomaLogic, Southwest Research Institute, Southwest Transplant Alliance, SpineThera, Spotlight Innovation, SQI Diagnostics, St. Jude Children's Research Hospital, Standigm, Stanford University, Steeper Group, Stempeutics, Storm ID, StrideBio, Strides Arcolab, StrongPath, Stryker, Summit Therapeutics, Sun Pharmaceutical, Surgalign, SurGenTec, Surgical Specialties, Sway Medical, Swedish Bactiguard, Swedish Orphan Biovitrum, SWK Funding, Symic Biomedical, Synartro, Synpromics, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda Pharmaceutical, Technology Consult Berlin, Teijin, Tenex Health, Teva Pharmaceutical Industries, Texas Christian University, The Arthritis Society, The Cyprus Institute of Neurology and Genetics, Theramex, THINK Surgical, Thuasne and Townsend Design, TissueGene, Tissue Genesis, Tissue Regenix, TiumBio, Toshiba Medical Systems Corporation, Total Joint Orthopedics, Touch Bionics, Tow Foundation, TR-Pharm, TracPatch Health, Transcenta, Transdermal Delivery Solutions, TrialSpark, Trice Medical, Tufts University, Turner Imaging Systems, UCB, Ultragenyx Pharmaceuticals, Unilife, United Orthopedic Group, University City Science Center, University of Basel, University of Bern, University of British Columbia, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Edinburgh, University of Florida, University of Illinois, University of Illinois Urbana-Champaign, University of Iowa, University of Kansas, University of Kentucky, University of Lausanne, University of Liverpool, University of L’Aquila, University of Massachusetts, University of Massachusetts Medical School, University of Miami, University of Michigan, University of Minnesota, University of Missouri, University of Oklahoma, University of Ottowa, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Sydney, University of Texas, University of Texas Southwestern Medical Center, University of Vermont, University of Verona, University of Virginia, University of Washington, US Army, V ClinBio, Verily, Vertex Pharmaceuticals, VIB, Victoria University, Virginia Commonwealth University, Virpax Pharmaceuticals, Viscogliosi Brothers, VISEN Pharmaceuticals, Vivo Capital, Vizient, Voronoi, Voyager Therapeutics, Wake Forest University, Wake Research Associates, Walloon Region Investment Fund, Weill Cornell Medical College, WellDyne, WishBone Medical, Wittenstein, WorldCare Clinical, Wright Medical, WuXi Biologics, Xlife Sciences, XR Medical Group, Xtant Medical, Yale University, Yissum Research Development, Yposkesi, Zebra Medical Vision, Zimmer Biomet, Zoetis

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838